Rotigotine may improve sleep architecture in Parkinson's disease: A double-blind, Randomized, Placebo-controlled polysomnographic study

Mariangela Pierantozzi, Fabio Placidi, Claudio Liguori, Maria Albanese, Paola Imbriani, Maria Grazia Marciani, Nicola Biagio Mercuri, Paolo Stanzione, Alessandro Stefani

Research output: Contribution to journalArticle

Abstract

Background/Objectives: Growing evidence demonstrates that in Parkinson's Disease (PD) sleep disturbances are frequent and difficult to treat. Since the efficacy of rotigotine on sleep is corroborated by studies lacking polysomnography (PSG), this study explores the possible rotigotine-mediated impact on PSG parameters in PD patients. Methods: This is a randomized, double-blind, placebo-controlled, parallel-group study to determine the efficacy of rotigotine vs placebo on PSG parameters in moderately advanced PD patients. An unusual protocol was utilized, since patches were maintained from 18:00 h to awakening, minimizing the possible diurnal impact on motor symptoms. All participants underwent sleep PSG recordings, subjective sleep questionnaires (Parkinson Disease Sleep Scale [PDSS], Pittsburgh Sleep Quality Index [PSQI]), and the assessment of early-morning motor disability. Results: We evaluated 42 PD patients (Hoehn & Yahr stages 2 and 3) with sleep impairment randomly assigned to active branch (N =21) or placebo (N = 21). Rotigotine significantly increased sleep efficiency and reduced both wakefulness after sleep onset and sleep latency compared to placebo. Moreover, the mean change in REM sleep quantity was significantly higher in the rotigotine than placebo group. The improvement of PSG parameters corresponded to the amelioration of PDSS and PSQI scores together with the improvement of patient morning motor symptoms. Conclusions: This study demonstrated the significant effect of rotigotine on sleep quality and continuity in PD patients by promoting sleep stability and increasing REM. The effectiveness of rotigotine on sleep may be ascribed to its pharmacokinetic/pharmacodynamic profile directly on both D1 and D2 receptors.

Original languageEnglish
Pages (from-to)140-144
Number of pages5
JournalSleep Medicine
Volume21
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Parkinson Disease
Sleep
Placebos
Polysomnography
N 0437
Wakefulness
REM Sleep
Pharmacokinetics

Keywords

  • Parkinson's disease
  • Polysomnography
  • REM
  • Rotigotine
  • Sleep

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pierantozzi, M., Placidi, F., Liguori, C., Albanese, M., Imbriani, P., Marciani, M. G., ... Stefani, A. (2016). Rotigotine may improve sleep architecture in Parkinson's disease: A double-blind, Randomized, Placebo-controlled polysomnographic study. Sleep Medicine, 21, 140-144. https://doi.org/10.1016/j.sleep.2016.01.016

Rotigotine may improve sleep architecture in Parkinson's disease : A double-blind, Randomized, Placebo-controlled polysomnographic study. / Pierantozzi, Mariangela; Placidi, Fabio; Liguori, Claudio; Albanese, Maria; Imbriani, Paola; Marciani, Maria Grazia; Mercuri, Nicola Biagio; Stanzione, Paolo; Stefani, Alessandro.

In: Sleep Medicine, Vol. 21, 01.05.2016, p. 140-144.

Research output: Contribution to journalArticle

Pierantozzi, M, Placidi, F, Liguori, C, Albanese, M, Imbriani, P, Marciani, MG, Mercuri, NB, Stanzione, P & Stefani, A 2016, 'Rotigotine may improve sleep architecture in Parkinson's disease: A double-blind, Randomized, Placebo-controlled polysomnographic study', Sleep Medicine, vol. 21, pp. 140-144. https://doi.org/10.1016/j.sleep.2016.01.016
Pierantozzi, Mariangela ; Placidi, Fabio ; Liguori, Claudio ; Albanese, Maria ; Imbriani, Paola ; Marciani, Maria Grazia ; Mercuri, Nicola Biagio ; Stanzione, Paolo ; Stefani, Alessandro. / Rotigotine may improve sleep architecture in Parkinson's disease : A double-blind, Randomized, Placebo-controlled polysomnographic study. In: Sleep Medicine. 2016 ; Vol. 21. pp. 140-144.
@article{7d64541969a143ac890d0f4233278f61,
title = "Rotigotine may improve sleep architecture in Parkinson's disease: A double-blind, Randomized, Placebo-controlled polysomnographic study",
abstract = "Background/Objectives: Growing evidence demonstrates that in Parkinson's Disease (PD) sleep disturbances are frequent and difficult to treat. Since the efficacy of rotigotine on sleep is corroborated by studies lacking polysomnography (PSG), this study explores the possible rotigotine-mediated impact on PSG parameters in PD patients. Methods: This is a randomized, double-blind, placebo-controlled, parallel-group study to determine the efficacy of rotigotine vs placebo on PSG parameters in moderately advanced PD patients. An unusual protocol was utilized, since patches were maintained from 18:00 h to awakening, minimizing the possible diurnal impact on motor symptoms. All participants underwent sleep PSG recordings, subjective sleep questionnaires (Parkinson Disease Sleep Scale [PDSS], Pittsburgh Sleep Quality Index [PSQI]), and the assessment of early-morning motor disability. Results: We evaluated 42 PD patients (Hoehn & Yahr stages 2 and 3) with sleep impairment randomly assigned to active branch (N =21) or placebo (N = 21). Rotigotine significantly increased sleep efficiency and reduced both wakefulness after sleep onset and sleep latency compared to placebo. Moreover, the mean change in REM sleep quantity was significantly higher in the rotigotine than placebo group. The improvement of PSG parameters corresponded to the amelioration of PDSS and PSQI scores together with the improvement of patient morning motor symptoms. Conclusions: This study demonstrated the significant effect of rotigotine on sleep quality and continuity in PD patients by promoting sleep stability and increasing REM. The effectiveness of rotigotine on sleep may be ascribed to its pharmacokinetic/pharmacodynamic profile directly on both D1 and D2 receptors.",
keywords = "Parkinson's disease, Polysomnography, REM, Rotigotine, Sleep",
author = "Mariangela Pierantozzi and Fabio Placidi and Claudio Liguori and Maria Albanese and Paola Imbriani and Marciani, {Maria Grazia} and Mercuri, {Nicola Biagio} and Paolo Stanzione and Alessandro Stefani",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.sleep.2016.01.016",
language = "English",
volume = "21",
pages = "140--144",
journal = "Sleep Medicine",
issn = "1389-9457",
publisher = "Elsevier",

}

TY - JOUR

T1 - Rotigotine may improve sleep architecture in Parkinson's disease

T2 - A double-blind, Randomized, Placebo-controlled polysomnographic study

AU - Pierantozzi, Mariangela

AU - Placidi, Fabio

AU - Liguori, Claudio

AU - Albanese, Maria

AU - Imbriani, Paola

AU - Marciani, Maria Grazia

AU - Mercuri, Nicola Biagio

AU - Stanzione, Paolo

AU - Stefani, Alessandro

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background/Objectives: Growing evidence demonstrates that in Parkinson's Disease (PD) sleep disturbances are frequent and difficult to treat. Since the efficacy of rotigotine on sleep is corroborated by studies lacking polysomnography (PSG), this study explores the possible rotigotine-mediated impact on PSG parameters in PD patients. Methods: This is a randomized, double-blind, placebo-controlled, parallel-group study to determine the efficacy of rotigotine vs placebo on PSG parameters in moderately advanced PD patients. An unusual protocol was utilized, since patches were maintained from 18:00 h to awakening, minimizing the possible diurnal impact on motor symptoms. All participants underwent sleep PSG recordings, subjective sleep questionnaires (Parkinson Disease Sleep Scale [PDSS], Pittsburgh Sleep Quality Index [PSQI]), and the assessment of early-morning motor disability. Results: We evaluated 42 PD patients (Hoehn & Yahr stages 2 and 3) with sleep impairment randomly assigned to active branch (N =21) or placebo (N = 21). Rotigotine significantly increased sleep efficiency and reduced both wakefulness after sleep onset and sleep latency compared to placebo. Moreover, the mean change in REM sleep quantity was significantly higher in the rotigotine than placebo group. The improvement of PSG parameters corresponded to the amelioration of PDSS and PSQI scores together with the improvement of patient morning motor symptoms. Conclusions: This study demonstrated the significant effect of rotigotine on sleep quality and continuity in PD patients by promoting sleep stability and increasing REM. The effectiveness of rotigotine on sleep may be ascribed to its pharmacokinetic/pharmacodynamic profile directly on both D1 and D2 receptors.

AB - Background/Objectives: Growing evidence demonstrates that in Parkinson's Disease (PD) sleep disturbances are frequent and difficult to treat. Since the efficacy of rotigotine on sleep is corroborated by studies lacking polysomnography (PSG), this study explores the possible rotigotine-mediated impact on PSG parameters in PD patients. Methods: This is a randomized, double-blind, placebo-controlled, parallel-group study to determine the efficacy of rotigotine vs placebo on PSG parameters in moderately advanced PD patients. An unusual protocol was utilized, since patches were maintained from 18:00 h to awakening, minimizing the possible diurnal impact on motor symptoms. All participants underwent sleep PSG recordings, subjective sleep questionnaires (Parkinson Disease Sleep Scale [PDSS], Pittsburgh Sleep Quality Index [PSQI]), and the assessment of early-morning motor disability. Results: We evaluated 42 PD patients (Hoehn & Yahr stages 2 and 3) with sleep impairment randomly assigned to active branch (N =21) or placebo (N = 21). Rotigotine significantly increased sleep efficiency and reduced both wakefulness after sleep onset and sleep latency compared to placebo. Moreover, the mean change in REM sleep quantity was significantly higher in the rotigotine than placebo group. The improvement of PSG parameters corresponded to the amelioration of PDSS and PSQI scores together with the improvement of patient morning motor symptoms. Conclusions: This study demonstrated the significant effect of rotigotine on sleep quality and continuity in PD patients by promoting sleep stability and increasing REM. The effectiveness of rotigotine on sleep may be ascribed to its pharmacokinetic/pharmacodynamic profile directly on both D1 and D2 receptors.

KW - Parkinson's disease

KW - Polysomnography

KW - REM

KW - Rotigotine

KW - Sleep

UR - http://www.scopus.com/inward/record.url?scp=84975495446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975495446&partnerID=8YFLogxK

U2 - 10.1016/j.sleep.2016.01.016

DO - 10.1016/j.sleep.2016.01.016

M3 - Article

VL - 21

SP - 140

EP - 144

JO - Sleep Medicine

JF - Sleep Medicine

SN - 1389-9457

ER -